Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.56 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.56 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 9/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120610 | 1.00 | ACHE (0.65) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL1120608 | 1.00 | ACHE (0.65) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL24078860 | 0.93 | ACHE (0.66) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL19370259 | 0.93 | ACHE (0.66) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL4803780 | 0.92 | ALDH1A1 (0.61) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL4803787 | 0.92 | ALDH1A1 (0.61) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL4803791 | 0.92 | ALDH1A1 (0.61) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL24601162 | 0.91 | ALDH1A1 (0.70) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL24601281 | 0.90 | ACHE (0.63) | ACHEALDH1A1LMNATP53MAPT | |
| SCHEMBL6320952 | 0.90 | ALDH1A1 (0.57) | ACHEALDH1A1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943251-B8 | A1 ADENOSINE RECEPTOR AGONISTS | GILEAD PALO ALTO INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1943251-B1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ELZEIN ELFATIH | 2009-05-28 | — | — | US | disclosed |
| US-7488720-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1943251-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1883646-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007047401-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | CV THERAPEUTICS, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006125190-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | ACHE 2632/4885ALDH1A1 129/4885LMNA 2001/4885 |
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | ACHE 1907/4885ALDH1A1 77/4885LMNA 1717/4885 |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | FFAR1, ADORA3, ADORA1 | ACHE 1739/4885ALDH1A1 472/4885LMNA 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.